Attovia Therapeutics, Inc. (ATTO) Income Statement
ATTO 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsATTO revenue and net income
Where ATTO's revenue goes
2025Each bar shows an amount and its share of revenue. ATTO kept −4,490.9% of revenue as net income.
ATTO profit margins
ATTO growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
ATTO quarterly EPS vs estimates
Attovia Therapeutics beat the analyst EPS estimate in 0 of the last 1 quarters. Next report: December 2, 2026 (estimate $-0.74).
ATTO income statement
| 2025 | 2024 | |
|---|---|---|
| Revenue | $1.4M | $0 |
| Cost of revenue | $804,000 | $313,000 |
| Gross profit | $546,000 | −$313,000 |
| Research & development | $54.2M | $33.9M |
| Sales, general & admin | $14.4M | $7.7M |
| Total operating expenses | $67.7M | $41.2M |
| Operating income | −$67.2M | −$41.6M |
| Interest income | $6.6M | $3.4M |
| Income before taxes | −$60.6M | −$39.8M |
| Net income | −$60.6M | −$39.8M |
| EBITDA | −$66.4M | −$41.2M |
| EPS (diluted) | −$2.36 | — |
| Gross margin | 40.4% | — |
| Operating margin | −4,974.7% | — |
| Net margin | −4,490.9% | — |
| Jun '26 | Mar '26 | Jun '25 | Mar '25 | |
|---|---|---|---|---|
| Revenue | $450,000 | $0 | $0 | $0 |
| Cost of revenue | $246,000 | $242,000 | — | $143,000 |
| Gross profit | $204,000 | −$242,000 | — | −$143,000 |
| Research & development | $18.9M | $16.7M | $13.6M | $11.9M |
| Sales, general & admin | $3.3M | $3.2M | $3.0M | $4.2M |
| Total operating expenses | $22.0M | $19.7M | $16.6M | $16.0M |
| Operating income | −$21.8M | −$20.0M | −$16.6M | −$16.1M |
| Interest income | $1.1M | $1.3M | $2.0M | $1.1M |
| Income before taxes | −$20.7M | −$18.7M | −$14.4M | −$15.2M |
| Net income | −$20.7M | −$18.7M | −$14.4M | −$15.2M |
| EBITDA | −$21.6M | −$19.7M | −$16.4M | −$16.0M |
| EPS (diluted) | −$4.88 | — | — | — |
| Gross margin | 45.3% | — | — | — |
| Operating margin | −4,845.1% | — | — | — |
| Net margin | −4,597.1% | — | — | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in ATTO's financial statements (latest annual report filed December 31, 2025); data from EODHD. Sales, general & administrative expenses include sales and marketing.
ATTO financial results
In fiscal year 2025 (ended December 31, 2025), Attovia Therapeutics reported revenue of $1.4 million. It had a net loss of $60.6 million, a net profit margin of −4,490.9%. Diluted earnings per share came to −$2.36.
See the ATTO stock overview for the latest quote and news, or the ATTO chart for price history and technical indicators.
ATTO income statement FAQ
What is Attovia Therapeutics's annual revenue?
Attovia Therapeutics reported total revenue of $1.4 million for fiscal year 2025, which ended on December 31, 2025.
Is Attovia Therapeutics profitable?
No. Attovia Therapeutics reported a net loss of $60.6 million in fiscal 2025, a net profit margin of −4,490.9%; its operating margin was −4,974.7%.
What is Attovia Therapeutics's gross margin?
Attovia Therapeutics's gross margin was 40.4% in fiscal 2025: for every $100 of revenue, Attovia Therapeutics kept $40 after the direct cost of its products and services.
How much does Attovia Therapeutics spend on research and development?
Attovia Therapeutics spent $54.2 million on research and development in fiscal 2025, 4,011.3% of revenue.
What are Attovia Therapeutics's earnings per share?
Attovia Therapeutics earned $-2.36 per diluted share in fiscal 2025.
When will Attovia Therapeutics report its next earnings?
Attovia Therapeutics is expected to report results for the quarter ending September 30, 2026 on December 2, 2026.
When does Attovia Therapeutics's fiscal year end?
Attovia Therapeutics's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on December 31, 2025.